Research graph
References from Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Diagnosis and treatment of chronic lymphocytic leukemia: a review
10.1001/jama.2023.1946 · 2023 · External reference
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
10.3324/haematol.2017.182907 · 2018 · External reference
Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia
10.1001/jamaoncol.2014.218 · 2015 · External reference
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
10.1200/jco.21.01210 · 2021 · External reference
Managing toxicities of Bruton tyrosine kinase inhibitors
10.1182/hematology.2020000118 · 2020 · External reference
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
10.1056/nejmoa1509388 · 2015 · External reference
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
10.1056/nejmoa1400376 · 2014 · External reference
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
10.1056/nejmoa1509981 · 2016 · External reference
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
10.1182/blood.2018884940 · 2020 · External reference
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
10.1182/bloodadvances.2023009739 · 2023 · External reference
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
2023 · External reference
A global federated real-world data and analytics platform for research
10.1093/jamiaopen/ooad035 · 2023 · External reference
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
10.1182/blood.2022018818 · 2023 · External reference
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
10.1038/s41375-021-01485-x · 2022 · External reference
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
10.1182/bloodadvances.2021006434 · 2022 · External reference
